Expert discusses challenges contributing to high burnout rates among urologists
November 30th 2022"In Arkansas, for example, we now have half the urologists that there were 25 years ago, and that's with an increasing population. That's a representation of what's going on across the country," says R. Jonathan Henderson, MD.
Dr. Lowentritt highlights LUGPA discussion on urologic care for LGBTQ patients
November 22nd 2022“From a patient care standpoint, anything that opens the door and makes the patient feel more secure and open is going to lead to better outcomes for them and allow us to serve their needs best,” says Benjamin Lowentritt, MD, FACS.
Expert explains sequencing strategies in patients with mCRPC
November 13th 2022For patients with mCRPC who experience disease progression on novel hormonal agents (NHAs) and androgen deprivation therapy, it is important to consider when the NHA was received and whether docetaxel has been administered, explains Evan Y. Yu, MD.
Dr. Alicia Morgans details decision between doublets and triplets in mCSPC
November 12th 2022ADT intensification through doublet and triplet regimens has become standard for most patients with metastatic castration-sensitive prostate cancer, Alicia Morgans, MD, MPH, explained in a presentation at the 2022 LUGPA Annual Meeting.
Tips for optimizing an advanced prostate cancer clinic
November 11th 2022In an interview during the 2022 LUGPA Annual Meeting, Jason M. Hafron, MD, shared advice on optimizing advanced prostate cancer clinics, recapped the biggest advances in urologic cancer treatment in 2022, and discussed how Jelmyto treatment for UTUC has evolved over time.
Dr. Siefker-Radtke on the biggest recent advances in urothelial cancer care
November 11th 2022"It really is a fun time to be doing urothelial cancer research, as we see patients living longer, with more durable responses, impacting their overall survival and long-term outcomes," says Arlene Siefker-Radtke, MD.
Dr. Hafron on LUGPA 2021 and the rapidly evolving prostate and bladder cancer treatment landscapes
November 22nd 2021In this interview, Jason M. Hafron, MD, discusses the “buzz” surrounding the meeting and touches on clinical topics including germline and somatic testing, PARP inhibitors, and mitomycin-containing reverse thermal gel (Jelmyto).
Dr. Hafron on PARP inhibitors in prostate cancer
November 16th 2021“I think as our understanding of mutations [and] our understanding the PARP inhibitors [grows], if the data pans out, we'll be using these earlier and earlier in patients, which I think we'll [will allow us to] see probably more benefit,” says Jason M. Hafron, MD.